Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)
21.59 -0.46 (-2.09%) 14:54 ET [NASDAQ]
21.57 x 17 21.62 x 100
Realtime by (Cboe BZX)
21.57 x 17 21.62 x 100
Realtime 22.25 +0.20 (+0.91%) 09:29 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
21.35
Day High
22.26
Open 22.26
Previous Close 22.05 22.05
Volume 480,417 480,417
Avg Vol 877,086 877,086
Stochastic %K 17.02% 17.02%
Weighted Alpha +44.40 +44.40
5-Day Change -1.79 (-7.70%) -1.79 (-7.70%)
52-Week Range 13.49 - 24.64 13.49 - 24.64
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,629,970
  • Shares Outstanding, K 119,273
  • Annual Sales, $ 398,200 K
  • Annual Income, $ 71,410 K
  • EBIT $ 211 M
  • EBITDA $ 244 M
  • 60-Month Beta 0.80
  • Price/Sales 5.83
  • Price/Cash Flow 10.95
  • Price/Book 4.05

Options Overview Details

View History
  • Implied Volatility 57.42% ( +3.97%)
  • Historical Volatility 54.20%
  • IV Percentile 94%
  • IV Rank 65.83%
  • IV High 77.22% on 07/10/24
  • IV Low 19.27% on 06/17/24
  • Put/Call Vol Ratio 0.28
  • Today's Volume 110
  • Volume Avg (30-Day) 215
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 4,667
  • Open Int (30-Day) 4,012

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.49
  • Number of Estimates 4
  • High Estimate 0.52
  • Low Estimate 0.46
  • Prior Year 0.49
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.35 +0.56%
on 02/21/25
Period Open: 22.92
24.64 -12.87%
on 01/30/25
-1.45 (-6.33%)
since 01/21/25
3-Month
19.15 +12.11%
on 01/08/25
Period Open: 21.12
24.64 -12.87%
on 01/30/25
+0.35 (+1.66%)
since 11/21/24
52-Week
13.49 +59.15%
on 02/22/24
Period Open: 13.71
24.64 -12.87%
on 01/30/25
+7.76 (+56.60%)
since 02/21/24

Most Recent Stories

More News
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

CPRX : 21.59 (-2.09%)
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

CPRX : 21.59 (-2.09%)
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

CPRX : 21.59 (-2.09%)
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

CPRX : 21.59 (-2.09%)
Catalyst Pharmaceuticals CEO Richard J. Daly to Present at 43rd Annual J.P. Morgan Healthcare Conference

Richard J. Daly, CEO of Catalyst Pharmaceuticals, will present at the J.P. Morgan Healthcare Conference on January 16, 2025.Quiver AI SummaryCatalyst Pharmaceuticals, Inc. announced that Richard J. Daly,...

CPRX : 21.59 (-2.09%)
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CPRX : 21.59 (-2.09%)
Insider Sale: Chief Med. & Reg. Officer of $CPRX (CPRX) Sells 3,369 Shares

GARY INGENITO, the Chief Med. & Reg. Officer of $CPRX ($CPRX), sold 3,369 shares of the company on 11-27-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 6.2%...

CPRX : 21.59 (-2.09%)
Catalyst Pharmaceuticals Achieves 452nd Rank on Deloitte's 2024 Technology Fast 500 List with 234% Revenue Growth

Catalyst Pharmaceuticals ranked 452 on Deloitte's Technology Fast 500 for achieving 234% revenue growth from 2020 to 2023.Quiver AI SummaryCatalyst Pharmaceuticals, Inc. announced that it ranked number...

CPRX : 21.59 (-2.09%)
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

CPRX : 21.59 (-2.09%)
Insider Sale: Director at $CPRX (CPRX) Sells 72,500 Shares

PATRICK J MCENANY, a director at $CPRX ($CPRX), sold 72,500 shares of the company on 11-20-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.6% of their shares....

CPRX : 21.59 (-2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights...

See More

Key Turning Points

3rd Resistance Point 23.07
2nd Resistance Point 22.81
1st Resistance Point 22.43
Last Price 21.59
1st Support Level 21.79
2nd Support Level 21.53
3rd Support Level 21.15

See More

52-Week High 24.64
Last Price 21.59
Fibonacci 61.8% 20.38
Fibonacci 50% 19.06
Fibonacci 38.2% 17.75
52-Week Low 13.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements